$5.45
5.38% today
Nasdaq, Feb 28, 05:20 pm CET
ISIN
US71722W1071
Symbol
PHAT
Sector
Industry

Phathom Pharmaceuticals Inc Stock price

$5.76
-0.80 12.20% 1M
-9.96 63.36% 6M
-2.36 29.06% YTD
-4.39 43.25% 1Y
-12.37 68.23% 3Y
-26.23 81.99% 5Y
-18.84 76.59% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.03 0.52%
ISIN
US71722W1071
Symbol
PHAT
Sector
Industry

Key metrics

Market capitalization $393.85m
Enterprise Value $578.16m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 22.01
P/S ratio (TTM) P/S ratio 14.99
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $26.27m
EBIT (operating result TTM) EBIT $-287.92m
Free Cash Flow (TTM) Free Cash Flow $-247.72m
Cash position $334.68m
EPS (TTM) EPS $-5.69
P/E forward negative
P/S forward 7.80
EV/Sales forward 11.45
Short interest 30.20%
Show more

Is Phathom Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Phathom Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Phathom Pharmaceuticals Inc forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Phathom Pharmaceuticals Inc forecast:

Buy
89%
Hold
11%

Financial data from Phathom Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
26 26
-
100%
- Direct Costs 4.51 4.51
705% 705%
17%
22 22
3,986% 3,986%
83%
- Selling and Administrative Expenses 270 270
198% 198%
1,028%
- Research and Development Expense 39 39
26% 26%
148%
-287 -287
100% 100%
-1,093%
- Depreciation and Amortization 0.79 0.79
41% 41%
3%
EBIT (Operating Income) EBIT -288 -288
100% 100%
-1,096%
Net Profit -339 -339
92% 92%
-1,292%

In millions USD.

Don't miss a Thing! We will send you all news about Phathom Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Phathom Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
4 days ago
FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, March 6, 2025, to report its fourth quarter and full year 2024 financial results and provide a business...
Neutral
GlobeNewsWire
about one month ago
FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Thursday, February 6, 2025...
Neutral
GlobeNewsWire
3 months ago
FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today it has submitted a Citizen Petition (CP) with the U.S. Food and Drug Administration (FDA). The petition formally requests correction of the Orange Book listin...
More Phathom Pharmaceuticals Inc News

Company Profile

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. It focuses on its vonoprazan product, an oral small molecule potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Head office United States
CEO Terrie Curran
Employees 452
Founded 2018
Website www.phathompharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today